A transcriptomic signature for prostate cancer relapse prediction identified from the differentially expressed genes between TP53 mutant and wild-type tumors.

Zhang W, Zhang K. A transcriptomic signature for prostate cancer relapse prediction identified from the differentially expressed genes between TP53 mutant and wild-type tumors. Sci Rep. 2022 06 22; 12(1):10561.

View in: PubMed

subject areas

Humans
Male
Neoplasm Recurrence, Local
Prognosis
Prostatic Neoplasms
Tumor Suppressor Protein p53

authors with profiles

Kun Zhang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support